Annual General Meeting of Q-Med AB (publ).STOCKHOLM, Sweden -- The Board of Directors of Q-Med AB (publ) (STO:QMED) has of today published a notice to attend the Annual General Meeting, which will be held on Thursday May 3 at 3 p.m. on Q-Med's new premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning Upsala Nya Tidning or UNT is a regional daily newspaper published in Uppsala (older spelling Upsala), Sweden. The name means Upsala New Newspaper and the first issue appeared in 1890. It has a circulation of about 60,000 (in 2003). , Svenska Dagbladet and in Post- och Inrikes Tidningar Post- och Inrikes Tidningar or PoIT (Swedish for "Post and Domestic Newspaper") is the government newspaper and gazette of Sweden, and the country's official notification medium for announcements like bankruptcy declarations or auctions. (Swedish Offical Gazette). The complete notice of the Annual General Meeting in English can be found on the corporate web site www.q-med.com. Q-Med AB (publ) The Board Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) [TM] for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR VUR Vesicoureteral reflux, see there , (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX OMX Office Max (stock symbol) Nordic Stock Exchange in Stockholm. NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med AB. In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion